Demographic and health care service utilization by 4417 patients with hidradenitis suppurativa - 23/11/17
, Meir Babaev, MD b, Tamar Freud, PhD c, Shmuel Tiosano, MD, MPH d, e, Nadav Pam, MD f, Amir Horev, MD a, b, Jacob Dreiher, MD, MPH c, g, Daniel A. Vardy, MD, MSc a, b, Doron Comaneshter, MHA, PhD h, Arnon D. Cohen, MD, MPH, PhD c, hAbstract |
Background |
Data on the health care utilization of patients with hidradenitis suppurativa (HS) in primary care settings are scarce.
Objective |
To investigate the health care service utilization of patients with HS.
Methods |
In a cross-sectional study, patients with HS were compared with 2 age- and sex-matched control groups—general population enrollees of Clalit Health Services and a group of patients with psoriasis. Health care services data included inpatient and outpatient community clinic visits and pharmacy claims for topical and systemic treatments. Multivariate analysis of the data for patients with HS and controls was performed.
Results |
The study included 4417 patients with HS, 22,085 general population enrollees, and 4417 patients with psoriasis. On the basis of multivariate analyses, patients with HS had more annual dermatology clinic visits compared with the general population enrollees (odds ratio [OR], 6.49; 95% confidence interval [CI], 7.06-5.97) and patients with psoriasis (OR, 1.32; 95% CI, 1.44-1.21), more annual surgical clinic visits (OR, 3.78; 95% CI 3.28-4.36 and OR, 1.65; 95% CI, 1.42-1.91, respectively), and more hospitalizations (OR, 2.21; 95% CI, 1.89-2.56 and OR, 1.51; 95% CI, 1.28-1.78, respectively).
Limitations |
Underestimation of HS frequency was possible.
Conclusions |
The burden on health care systems due to patients with HS is greater than that due to patients with psoriasis and the general population.
Le texte complet de cet article est disponible en PDF.Key words : drug utilization, epidemiology, health care utilization, hidradenitis suppurativa, psoriasis
Abbreviations used : BMI, CHS, CI, HS, OR
Plan
| Drs Shalom and Babaev contributed equally to this article. |
|
| Supported by an independent research grant from Abbvie Inc. The company was not involved in any part of the study design, execution, or writing. |
|
| Disclosure: Dr Cohen has served as an advisor, investigator, or speaker for Abbvie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer, and Rafa. Drs Shalom, Babaev, Freud, Tiosano, Pam, Horev, Dreiher, Vardy, and Comaneshter have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 77 - N° 6
P. 1047 - décembre 2017 Retour au numéro
Article précédent
- Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa
- Iltefat H. Hamzavi, Murali Sundaram, Cynthia Nicholson, Marko Zivkovic, Angela Parks-Miller, Jianyi Lee, Jingbo Yi, Yihua Gu, Martin M. Okun, Arijit Ganguli, Steve R. Arikian
- Lichen planus affecting the female genitalia: A retrospective review of patients at Mayo Clinic
- Caoimhe M.R. Fahy, Rochelle R. Torgerson, Mark D.P. Davis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?